Organization | Swiss Paraplegic Centre Nottwil

Swiss Paraplegic Centre Nottwil Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Nottwil Switzerland (1990)

Organization Overview

First Clinical Trial

2012

NCT01591226

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Swiss Paraplegic Centre Nottwil | Swiss Paraplegic Research Nottwil

Active Ingredients

Drugs in Phase 4 Trials (1)

uro-vaxom (1 trial)

Drugs in Phase 3 Trials (1)

vitamin d3 (2 trials)

Drugs in Other Trials (17)

beetroot juice (2 trials)

bifidobacterium lactis (1 trial)

caffeine (1 trial)

enterococcus faecium (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus paracasei (1 trial)

lactobacillus plantarum (1 trial)

lactobacillus salivarius (1 trial)

lactococcus lactis (1 trial)

mannitol (2 trials)

oat bran (1 trial)

opiate with bolus (1 trial)

rivaroxaban (xarelto) (1 trial)

sodium chloride (1 trial)

sodium citrate (1 trial)

sodium nitrate (2 trials)

water (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Communicable Diseases (Phase 4)

Infections (Phase 4)

Spinal Cord Injuries (Phase 4)

Urinary Tract Infections (Phase 4)

Vitamin D Deficiency (Phase 3)

Wounds and Injuries (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial APIs: 19